Company news
Verrica Pharmaceuticals Inc. news in 2023
Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2023, newest first.
Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London
November 9, 2023
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 8, 2023
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
August 30, 2023
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
August 23, 2023
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
August 9, 2023
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 7, 2023
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
August 2, 2023
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
July 25, 2023
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8: 30 am ET
July 23, 2023
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
July 20, 2023
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
May 30, 2023
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
May 9, 2023
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
May 8, 2023
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
April 11, 2023
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
March 5, 2023
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
February 27, 2023
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
February 26, 2023
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
February 20, 2023
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
January 23, 2023
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
January 3, 2023
Calls in 2023
Decks in 2023
- Investor Presentation (November 2023)
Investor deck · 54 slides · November 2023
- Investor Presentation (September 2023)
Investor deck · 54 slides · September 2023
- Corporate Update (July 2023)
Corporate update · 23 slides · Jul 24, 2023
- Investor Presentation (July 2023)
Investor deck · 54 slides · July 2023
- Investor Presentation (February 2023)
Investor deck · 52 slides · Feb 2, 2023